CTLA4 and metastatic melanoma: The introduction of immunotherapy, particularly programmed death 1 (PD-1) inhibitors such as nivolumab and pembrolizumab, together with the cytotoxic T-cell-associated antigen 4 inhibitor (CTLA4) such as ipilimumab in combination with nivolumab, significantly extended overall survival in metastatic melanoma.